Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa
Encouraging results from a Phase 2b study. The trial enrolled adult volunteers from Finland who travelled to Benin after receiving ETVAX® or placebo. The study results confirm the excellent safety and overall positive immunogenicity of ETVAX®, as well as a significant protective efficacy of 56% against all severe diarrhea, independent of pathogen.